DayTwo, the Israel-based creator of a microbiome health management app, raised $12m on Tuesday in a series A round featuring healthcare group Johnson & Johnson’s corporate venturing unit, Johnson & Johnson Innovation – JJDC.
Medical research firm Mayo Clinic also invested in the round, as did venture capital firm Seventure Partners’ Health for Life Capital fund, DayTwo co-founder Marius Nacht and undisclosed private investors.
DayTwo has developed an app that measures a user’s post-meal blood sugar and uses machine learning to offer them personalised meal planners based on their gut microbiome profiles.
The series A funding will be used to extend DayTwo’s research into the gut microbiome, and to grow its product, engineering and data science teams in Tel Aviv, Israel, and San Francisco, USA.
DayTwo will also expand the research partnership with Mayo Clinic and add to its network of medical research partners.
Lihi Segal, chief executive of DayTwo, said: “DayTwo has brought actionable, evidence-based science down to a mobile app, to make personalised nutrition easy and convenient for the first time.
“This enables DayTwo to impact the lives of hundreds of millions of people who struggle with diet and nutrition-related health risks every day.”